Immunocore Holdings Plc: Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Immunocore Holdings Plc is a commercial-stage biotechnology company focused on immunomodulating medicines. Its lead product, KIMMTRAK (tebentafusp), is approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma. The company operates a single segment: immunotherapies.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $97.96 million | $191.85 million | $75.40 million | $145.90 million |
| Net Loss | $(10.30) million | $(5.28) million | $(11.62) million | $(36.05) million |
| Net Loss Per Share | $(0.20) | $(0.11) | $(0.23) | $(0.72) |
| Operating Cash Flow (YTD) | $26.40 million | $26.40 million | $18.89 million | $18.89 million |
| Cash & Marketable Securities | $882.81 million | $882.81 million | $820.38 million | $820.38 million |
| Debt (Convertible Notes) | $392.06 million | $392.06 million | $391.01 million | $391.01 million |
Note: Cash and Marketable Securities combined total $882.81 million as of June 30, 2025 ($487.93M cash + $394.88M securities).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30.0% year-over-year in Q2 2025, driven by a 15.3% increase in U.S. sales and a 114.5% surge in European sales. International sales declined 80.7% due to timing of orders.
- Improved Profitability: The net loss narrowed significantly to $10.3 million in Q2 2025 from $11.6 million in Q2 2024. On a year-to-date basis, the loss improved dramatically to $5.3 million from $36.1 million in the prior year.
- R&D Expenses: R&D expenses rose 35.1% in Q2 2025 to $69.0 million. This increase was primarily due to higher external costs for "all other" clinical/preclinical programs (autoimmune focus) and increased spending on tebentafusp Phase 3 trials.
- Interest Income: Interest income decreased to $4.3 million in Q2 2025 from $6.2 million in Q2 2024, reflecting reduced cash balances due to the purchase of marketable securities in the prior year.
Guidance, Outlook, and Risks
- Liquidity: Management expects existing cash, marketable securities, and anticipated revenue to fund operations for at least the next 12 months. The company holds $882.8 million in liquid assets.
- Upcoming Payments: The company expects to pay approximately $65.0 million in the second half of 2025 related to accrued revenue deductions (rebates/chargebacks).
- Clinical Progress: Over 150 clinical trial sites have been activated for the PRISM-MEL-301 Phase 3 trial evaluating brenetafusp + nivolumab. Data for IMC-I109V (HBV/HCC) is expected in November 2025.
- Recent Developments: A new distribution agreement was signed with Er-Kim for Turkey, the Middle East, North Africa, and the Caucasus. A global Class III voluntary recall was initiated for one batch of KIMMTRAK in June 2025; management does not expect a material financial impact.
- Risks: Key risks include the ability to maintain regulatory approval, pricing negotiations in Europe (specifically France and Germany), and the need for additional financing to support long-term clinical development. The company is also exposed to foreign currency fluctuations, though recent movements resulted in a net gain.
Investor Verification Checklist
- Rebate Accruals: Verify the $149.5 million in accrued revenue deductions and the sensitivity analysis indicating a 20% change in estimates could impact revenue by $2.0 million.
- Debt Maturity: Confirm the terms of the $402.5 million convertible senior notes maturing in February 2030 and the 2.50% coupon rate.
- European Expansion: Monitor the impact of completed price negotiations in France and Germany on future revenue recognition and gross margins.
- Cash Burn vs. Revenue: Assess the trajectory of operating cash flow ($26.4M YTD) against the growing R&D spend to determine the runway without additional financing.
- Recall Impact: Track any updates regarding the June 2025 KIMMTRAK recall to ensure no material financial or reputational damage occurs.